Fig. 2: Structures for PROTACs 4 and 6 and control PROTACs 5 and 7.
From: Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2
We optimized PROTAC 2 to obtain PROTACs 4 and 6, as well as control compounds 5 and 7 which cannot recruit IAP.
